---
title: "CHINARES PHARMAs Innovative Drug BGM0504 for Weight Loss Has NDA Accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289760809.md"
description: "CHINARES PHARMAannounced that the New Drug Application (NDA) for its innovative weight loss drug, BGM0504 Injection, has been accepted by China's National Medical Products Administration. Developed jointly with subsidiaries, this acceptance marks the product's transition from clinical development to the NDA filing stage, a critical step toward commercialization."
datetime: "2026-06-15T09:40:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289760809.md)
  - [en](https://longbridge.com/en/news/289760809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289760809.md)
generator: "portal-rs"
---

# CHINARES PHARMAs Innovative Drug BGM0504 for Weight Loss Has NDA Accepted

CHINARES PHARMA (03320.HK) -0.070 (-1.446%) Short selling $5.79M; Ratio 16.819% announced that the new drug application (NDA) for the innovative drug "BGM0504 Injection", jointly developed by its subsidiary China Resources Sanjiu Medical & Pharmaceutical and BrightGene Bio-Medical Technology, for the weight loss indication has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. This marks the product's transition from clinical development to the NDA filing stage, taking a critical step toward commercialization.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-15 16:25.)

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [000999.CN](https://longbridge.com/en/quote/000999.CN.md)
- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [Bank of America Securities Keeps Their Buy Rating on China Resources Pharmaceutical Group Ltd. (640)](https://longbridge.com/en/news/297101685.md)
- [CR Pharmaceutical Holdings, China Resources Pharmaceutical unit, posts 1H net profit RMB 5.18 billion](https://longbridge.com/en/news/297497474.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [20:00 ETWuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion](https://longbridge.com/en/news/297441220.md)
- [Luye Pharma Delivers Higher H1 Profit Despite Revenue Decline](https://longbridge.com/en/news/297428133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**